PuSH - Publication Server of Helmholtz Zentrum München

van Noort, V.* ; Schölch, S.* ; Iskar, M.* ; Zeller, G.* ; Ostertag, K.* ; Schweitzer, C.* ; Werner, K.* ; Weitz, J.* ; Koch, M.* ; Bork, P.*

Novel drug candidates for the treatment of metastatic colorectal cancer through global inverse gene-expression profiling.

Cancer Res. 74, 5690-5699 (2014)
DOI Order publishers version
Open Access Green as soon as Postprint is submitted to ZB.
Drug-induced gene-expression profiles that invert disease profiles have recently been illustrated to be a starting point for drug repositioning. In this study, we validate this approach and focus on prediction of novel drugs for colorectal cancer, for which there is a pressing need to find novel antimetastatic compounds. We computationally predicted three novel and still unknown compounds against colorectal cancer: citalopram (an antidepressant), troglitazone (an antidiabetic), and enilconazole (a fungicide). We verified the compounds by in vitro assays of clonogenic survival, proliferation, and migration and in a subcutaneous mouse model. We found evidence that the mode of action of these compounds may be through inhibition of TGFβ signaling. Furthermore, one compound, citalopram, reduced tumor size as well as the number of circulating tumor cells and metastases in an orthotopic mouse model of colorectal cancer. This study proposes citalopram as a potential therapeutic option for patients with colorectal cancer, illustrating the potential of systems pharmacology.
Altmetric
Additional Metrics?
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
ISSN (print) / ISBN 0008-5472
e-ISSN 1538-7445
Journal Cancer Research
Quellenangaben Volume: 74, Issue: 20, Pages: 5690-5699 Article Number: , Supplement: ,
Publisher American Association for Cancer Research (AACR)
Publishing Place Philadelphia, Pa.
Reviewing status Peer reviewed
Institute(s) Institute for Pancreatic Beta Cell Research (IPI)